ABCB5 and recessive dystrophic epidermolysis bullosa: To this end, we conducted an exploratory post-hoc analysis of the above-referenced clinical trial in RDEB patients, specifically focusing on the development and healing kinetics of wounds that were not present at baseline during 12 weeks of systemic treatment with ABCB5+ MSCs.